Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Research article

Cardiovascular disease risk among Chinese antiretroviral-naïve adults with advanced HIV disease

Authors: Fuping Guo, Evelyn Hsieh, Wei Lv, Yang Han, Jing Xie, Yanling Li, Xiaojing Song, Taisheng Li

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

Cardiovascular disease (CVD) is an important cause of mortality among HIV-infected patients, however little is known about the burden of CVD among this population in Asia. We sought to quantify prevalence of CVD risk factors, 10-year CVD risk, and patterns of CVD risk factor treatment in a group of individuals with HIV in China.

Methods

We retrospectively analyzed baseline data from treatment-naïve HIV-infected adults enrolled in two multicenter clinical trials in China. Data regarding CVD risk factors such as smoking, hypertension, diabetes, dyslipidemia and obesity were assessed. The Framingham Risk Score (FRS) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) risk scores were calculated to estimate 10-year CVD risk. The American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score was used to identify individuals meeting criteria for lipid-lowering therapy.

Results

In total, 973 patients were included in the analysis. Mean age was 36.0 ± 10.2 years and 74.2% were men. The most common CVD risk factors were dyslipidemia (51.7%) and smoking (23.7%). Prevalence of hypertension, diabetes and obesity were 8.4%, 4.6% and 1.0%, respectively. Over 65% of patients had at least one CVD risk factor. The prevalence of 10-year risk of CVD ≥10% was 4.5% based upon FRS and was 3.3% based upon D:A:D risk score. Few patients with dyslipidemia, hypertension or diabetes were on treatment.

Conclusions

CVD risk factors are common but under-treated among Chinese treatment-naïve individuals with HIV. Future interventions should focus on training HIV providers to appropriately recognize and manage CVD risk factors during routine clinical assessments.
Literature
1.
go back to reference Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614–22.CrossRefPubMedPubMedCentral Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614–22.CrossRefPubMedPubMedCentral
2.
go back to reference Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:a:D study. AIDS. 2010;24(10):1537–48. Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:a:D study. AIDS. 2010;24(10):1537–48.
3.
go back to reference Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dube MP, et al. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008;118(2):198–210.CrossRefPubMedPubMedCentral Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dube MP, et al. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008;118(2):198–210.CrossRefPubMedPubMedCentral
4.
go back to reference Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte AD, De Wit S, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17(5):491–501.CrossRefPubMed Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte AD, De Wit S, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17(5):491–501.CrossRefPubMed
5.
go back to reference Martin-Iguacel R, Llibre JM, Friis-Moller N. Risk of cardiovascular disease in an aging HIV population: where are we now? Curr HIV/AIDS Rep. 2015;12(4):375–87.CrossRefPubMed Martin-Iguacel R, Llibre JM, Friis-Moller N. Risk of cardiovascular disease in an aging HIV population: where are we now? Curr HIV/AIDS Rep. 2015;12(4):375–87.CrossRefPubMed
6.
go back to reference Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010;24(8):1228–30.CrossRefPubMed Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010;24(8):1228–30.CrossRefPubMed
7.
go back to reference Kaplan RC, Kingsley LA, Sharrett AR, Li X, Lazar J, Tien PC, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007;45(8):1074–81.CrossRefPubMed Kaplan RC, Kingsley LA, Sharrett AR, Li X, Lazar J, Tien PC, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007;45(8):1074–81.CrossRefPubMed
8.
go back to reference Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.CrossRefPubMed Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.CrossRefPubMed
9.
go back to reference Edwards-Jackson N, Kerr S, Tieu H, Ananworanich J, Hammer S, Ruxrungtham K, et al. Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais. HIV Med. 2011;12(8):510–5.CrossRefPubMed Edwards-Jackson N, Kerr S, Tieu H, Ananworanich J, Hammer S, Ruxrungtham K, et al. Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais. HIV Med. 2011;12(8):510–5.CrossRefPubMed
10.
go back to reference Soliman EZ, Sharma S, Arasteh K, Wohl D, Achhra A, Tambussi G, et al. Baseline cardiovascular risk in the INSIGHT strategic timing of AntiRetroviral treatment (START) trial. HIV Med. 2015;16(Suppl 1):46–54.CrossRefPubMedPubMedCentral Soliman EZ, Sharma S, Arasteh K, Wohl D, Achhra A, Tambussi G, et al. Baseline cardiovascular risk in the INSIGHT strategic timing of AntiRetroviral treatment (START) trial. HIV Med. 2015;16(Suppl 1):46–54.CrossRefPubMedPubMedCentral
11.
go back to reference Yang ZJ, Liu J, Ge JP, Chen L, Zhao ZG, Yang WY, et al. Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and metabolic disorders study. Eur Heart J. 2012;33(2):213–20.CrossRefPubMed Yang ZJ, Liu J, Ge JP, Chen L, Zhao ZG, Yang WY, et al. Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and metabolic disorders study. Eur Heart J. 2012;33(2):213–20.CrossRefPubMed
12.
go back to reference Wu J, Cheng X, Qiu L, Xu T, Zhu G, Han J, et al. Prevalence and clustering of major cardiovascular risk factors in China: a recent cross-sectional survey. Medicine. 2016;95(10):e2712.CrossRefPubMedPubMedCentral Wu J, Cheng X, Qiu L, Xu T, Zhu G, Han J, et al. Prevalence and clustering of major cardiovascular risk factors in China: a recent cross-sectional survey. Medicine. 2016;95(10):e2712.CrossRefPubMedPubMedCentral
13.
go back to reference Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, et al. Rapid health transition in China, 1990-2010: findings from the global burden of disease study 2010. Lancet. 2013;381(9882):1987–2015.CrossRefPubMed Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, et al. Rapid health transition in China, 1990-2010: findings from the global burden of disease study 2010. Lancet. 2013;381(9882):1987–2015.CrossRefPubMed
14.
go back to reference Li T, Guo F, Li Y, Zhang C, Han Y, Lye W, et al. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China. Chin Med J. 2014;127(1):59–65.PubMed Li T, Guo F, Li Y, Zhang C, Han Y, Lye W, et al. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China. Chin Med J. 2014;127(1):59–65.PubMed
15.
go back to reference Fan HW, Guo FP, Li YJ, Li N, Li TS. Prevalence of thrombocytopenia among Chinese adult antiretroviral-naive HIV-positive patients. Chin Med J. 2015;128(4):459–64.CrossRefPubMedPubMedCentral Fan HW, Guo FP, Li YJ, Li N, Li TS. Prevalence of thrombocytopenia among Chinese adult antiretroviral-naive HIV-positive patients. Chin Med J. 2015;128(4):459–64.CrossRefPubMedPubMedCentral
16.
go back to reference Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obesity research. 1998; 6 Suppl 2:51S–209S. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obesity research. 1998; 6 Suppl 2:51S–209S.
17.
go back to reference Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on high blood pressure research. Hypertension. 2005;45(1):142–61.CrossRefPubMed Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on high blood pressure research. Hypertension. 2005;45(1):142–61.CrossRefPubMed
18.
go back to reference National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third report of the National Cholesterol Education Program (NCEP) expert Panel on Detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment Panel III) final report. Circulation. 2002;106(25):3143–421. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third report of the National Cholesterol Education Program (NCEP) expert Panel on Detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment Panel III) final report. Circulation. 2002;106(25):3143–421.
19.
go back to reference Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis. 2004;23(8):625–30.CrossRef Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis. 2004;23(8):625–30.CrossRef
20.
go back to reference Krikke M, Hoogeveen RC, Hoepelman AI, Visseren FL, Arends JE. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), systematic coronary risk evaluation for the Netherlands (SCORE-NL) and data collection on adverse events of anti-HIV drugs (D:a:D) risk prediction models. HIV Med. 2016;17(4):289–97.CrossRefPubMed Krikke M, Hoogeveen RC, Hoepelman AI, Visseren FL, Arends JE. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), systematic coronary risk evaluation for the Netherlands (SCORE-NL) and data collection on adverse events of anti-HIV drugs (D:a:D) risk prediction models. HIV Med. 2016;17(4):289–97.CrossRefPubMed
21.
go back to reference Law MG, Friis-Moller N, El-Sadr WM, Weber R, Reiss P, D'Arminio Monforte A, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:a:D study. HIV Med. 2006;7(4):218–30.CrossRefPubMed Law MG, Friis-Moller N, El-Sadr WM, Weber R, Reiss P, D'Arminio Monforte A, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:a:D study. HIV Med. 2006;7(4):218–30.CrossRefPubMed
22.
go back to reference Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglus ML, Garside D, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA. 1999;282(21):2012–8.CrossRefPubMed Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglus ML, Garside D, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA. 1999;282(21):2012–8.CrossRefPubMed
23.
go back to reference Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.CrossRefPubMed Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.CrossRefPubMed
24.
go back to reference Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med. 2007;26(30):5512–28.CrossRefPubMed Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med. 2007;26(30):5512–28.CrossRefPubMed
25.
go back to reference Luo L, Zeng Y, Li T, Lv W, Wang H, Guo F, et al. Prospective echocardiographic assessment of cardiac structure and function in Chinese persons living with HIV. Clin Infect Dis. 2014;58(10):1459–66.CrossRefPubMed Luo L, Zeng Y, Li T, Lv W, Wang H, Guo F, et al. Prospective echocardiographic assessment of cardiac structure and function in Chinese persons living with HIV. Clin Infect Dis. 2014;58(10):1459–66.CrossRefPubMed
26.
go back to reference Kuti MA, Adesina OA, Awolude OA, Ogunbosi BO, Fayemiwo SA, Akinyemi JO, et al. Dyslipidemia in ART-naive HIV-infected persons in Nigeria-implications for care. J Int Assoc Providers AIDS Care. 2014;14(4):355–9.CrossRef Kuti MA, Adesina OA, Awolude OA, Ogunbosi BO, Fayemiwo SA, Akinyemi JO, et al. Dyslipidemia in ART-naive HIV-infected persons in Nigeria-implications for care. J Int Assoc Providers AIDS Care. 2014;14(4):355–9.CrossRef
27.
go back to reference Manuthu EM, Joshi MD, Lule GN, Karari E. Prevalence of dyslipidemia and dysglycaemia in HIV infected patients. East Afr Med J. 2008;85(1):10–7.CrossRefPubMed Manuthu EM, Joshi MD, Lule GN, Karari E. Prevalence of dyslipidemia and dysglycaemia in HIV infected patients. East Afr Med J. 2008;85(1):10–7.CrossRefPubMed
28.
go back to reference Tadewos A, Addis Z, Ambachew H, Banerjee S. Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in southern Ethiopia: a cross-sectional comparative group study. AIDS Res Ther. 2012;9(1):31.CrossRefPubMedPubMedCentral Tadewos A, Addis Z, Ambachew H, Banerjee S. Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in southern Ethiopia: a cross-sectional comparative group study. AIDS Res Ther. 2012;9(1):31.CrossRefPubMedPubMedCentral
29.
go back to reference Armstrong C, Liu E, Okuma J, Spiegelman D, Guerino C, Njelekela M, et al. Dyslipidemia in an HIV-positive antiretroviral treatment-naive population in Dar es salaam, Tanzania. J Acquir Immune Defic Syndr. 2011;57(2):141–5.CrossRefPubMedPubMedCentral Armstrong C, Liu E, Okuma J, Spiegelman D, Guerino C, Njelekela M, et al. Dyslipidemia in an HIV-positive antiretroviral treatment-naive population in Dar es salaam, Tanzania. J Acquir Immune Defic Syndr. 2011;57(2):141–5.CrossRefPubMedPubMedCentral
30.
go back to reference Shen Y, Wang J, Wang Z, Qi T, Song W, Tang Y, et al. Prevalence of Dyslipidemia among antiretroviral-naive HIV-infected individuals in China. Medicine. 2015;94(48):e2201.CrossRefPubMedPubMedCentral Shen Y, Wang J, Wang Z, Qi T, Song W, Tang Y, et al. Prevalence of Dyslipidemia among antiretroviral-naive HIV-infected individuals in China. Medicine. 2015;94(48):e2201.CrossRefPubMedPubMedCentral
31.
go back to reference Liu J, Hong Y, D'Agostino Sr RB, Wu Z, Wang W, Sun J, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese multi-provincial cohort study. JAMA. 2004;291(21):2591–9.CrossRefPubMed Liu J, Hong Y, D'Agostino Sr RB, Wu Z, Wang W, Sun J, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese multi-provincial cohort study. JAMA. 2004;291(21):2591–9.CrossRefPubMed
32.
go back to reference De Socio GV, Martinelli C, Ricci E, Orofino G, Valsecchi L, Vitiello P, et al. Relations between cardiovascular risk estimates and subclinical atherosclerosis in naive HIV patients: results from the HERMES study. Int J STD AIDS. 2010;21(4):267–72.CrossRefPubMed De Socio GV, Martinelli C, Ricci E, Orofino G, Valsecchi L, Vitiello P, et al. Relations between cardiovascular risk estimates and subclinical atherosclerosis in naive HIV patients: results from the HERMES study. Int J STD AIDS. 2010;21(4):267–72.CrossRefPubMed
33.
go back to reference Rabkin M, Mutiti A, Chung C, Zhang Y, Wei Y, El-Sadr WM. Missed opportunities to address cardiovascular disease risk factors amongst adults attending an urban HIV Clinic in South Africa. PLoS One. 2015;10(10):e0140298.CrossRefPubMedPubMedCentral Rabkin M, Mutiti A, Chung C, Zhang Y, Wei Y, El-Sadr WM. Missed opportunities to address cardiovascular disease risk factors amongst adults attending an urban HIV Clinic in South Africa. PLoS One. 2015;10(10):e0140298.CrossRefPubMedPubMedCentral
34.
go back to reference Krikke M, Hoogeveen RC, Hoepelman A, Visseren F, Arends JE. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), systematic coronary risk evaluation for the Netherlands (SCORE-NL) and data collection on adverse events of anti-HIV drugs (D:a:D) risk prediction models. HIV Med. 2016;17(4):289–97.CrossRefPubMed Krikke M, Hoogeveen RC, Hoepelman A, Visseren F, Arends JE. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), systematic coronary risk evaluation for the Netherlands (SCORE-NL) and data collection on adverse events of anti-HIV drugs (D:a:D) risk prediction models. HIV Med. 2016;17(4):289–97.CrossRefPubMed
35.
go back to reference Bonfanti P, De Socio GL, Marconi P, Franzetti M, Martinelli C, Vichi F, et al. Is metabolic syndrome associated to HIV infection per se? Results from the HERMES study. Curr HIV Res. 2010;8(2):165–71.CrossRefPubMed Bonfanti P, De Socio GL, Marconi P, Franzetti M, Martinelli C, Vichi F, et al. Is metabolic syndrome associated to HIV infection per se? Results from the HERMES study. Curr HIV Res. 2010;8(2):165–71.CrossRefPubMed
36.
go back to reference De Socio GV, Ricci E, Parruti G, Calza L, Maggi P, Celesia BM, et al. Statins and aspirin use in HIV-infected people: gap between European AIDS clinical Society guidelines and clinical practice: the results from HIV-HY study. Infection. 2016;44(5):589–97.CrossRefPubMed De Socio GV, Ricci E, Parruti G, Calza L, Maggi P, Celesia BM, et al. Statins and aspirin use in HIV-infected people: gap between European AIDS clinical Society guidelines and clinical practice: the results from HIV-HY study. Infection. 2016;44(5):589–97.CrossRefPubMed
37.
go back to reference Boccara F, Miantezila Basilua J, Mary-Krause M, Lang S, Teiger E, Steg PG, et al. Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: results from the PACS-HIV lipids substudy. Am Heart J. 2017;183:91–101.CrossRefPubMed Boccara F, Miantezila Basilua J, Mary-Krause M, Lang S, Teiger E, Steg PG, et al. Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: results from the PACS-HIV lipids substudy. Am Heart J. 2017;183:91–101.CrossRefPubMed
38.
go back to reference De Socio GV, Ricci E, Maggi P, Parruti G, Pucci G, Di Biagio A, et al. Prevalence, awareness, treatment, and control rate of hypertension in HIV-infected patients: the HIV-HY study. Am J Hypertens. 2014;27(2):222–8.CrossRefPubMed De Socio GV, Ricci E, Maggi P, Parruti G, Pucci G, Di Biagio A, et al. Prevalence, awareness, treatment, and control rate of hypertension in HIV-infected patients: the HIV-HY study. Am J Hypertens. 2014;27(2):222–8.CrossRefPubMed
39.
go back to reference Zanni MV, Fitch KV, Feldpausch M, Han A, Lee H, Lu MT, et al. 2013 American College of Cardiology/American Heart Association and 2004 adult treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014;28(14):2061–70.CrossRefPubMedPubMedCentral Zanni MV, Fitch KV, Feldpausch M, Han A, Lee H, Lu MT, et al. 2013 American College of Cardiology/American Heart Association and 2004 adult treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014;28(14):2061–70.CrossRefPubMedPubMedCentral
40.
go back to reference Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, et al. Associations between immune depression and cardiovascular events in HIV infection. AIDS. 2013;27(17):2735–48.CrossRefPubMed Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, et al. Associations between immune depression and cardiovascular events in HIV infection. AIDS. 2013;27(17):2735–48.CrossRefPubMed
Metadata
Title
Cardiovascular disease risk among Chinese antiretroviral-naïve adults with advanced HIV disease
Authors
Fuping Guo
Evelyn Hsieh
Wei Lv
Yang Han
Jing Xie
Yanling Li
Xiaojing Song
Taisheng Li
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2358-0

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue